IMUX News

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at...

(RTTNews) - On Monday, Immunic, Inc. (IMUX), a biotechnology company developing oral treatments for neurological diseases, appointed Jaa Roberson as Chief People Officer, effective immediately. She will report to CEO Erik Lundgren and join the executive leadership team...

Immunic Appoints Jaa Roberson as Chief People Officer Immunic Appoints Jaa Roberson as Chief People OfficerPR NewswireNEW YORK, Oct. 19, 2026 Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial...

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPR...

Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 PR Newswire NEW YORK, Sept. 2, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology...

Immunic Appoints Chitrang Dav as Chief Data and Digital Officer Immunic Appoints Chitrang Dav as Chief Data and Digital Officer PR Newswire NEW YORK, Sept. 1, 2026 New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for...

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunic advances MS drug toward key Phase 3 data, expects results by year-end...

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire NEW YORK, Aug. 11, 2026 Leadership Team Expanded with Key Executive Appointments, Including Chief Executive...